COMPASS Pathways plc (NASDAQ:CMPS) Stock Holdings Reduced by PFM Health Sciences LP

PFM Health Sciences LP cut its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 58.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 451,267 shares of the company’s stock after selling 638,325 shares during the period. PFM Health Sciences LP owned 0.66% of COMPASS Pathways worth $2,843,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in CMPS. Logos Global Management LP lifted its stake in COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after acquiring an additional 901,050 shares during the last quarter. Renaissance Technologies LLC increased its position in COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock worth $1,593,000 after buying an additional 247,500 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in COMPASS Pathways during the second quarter valued at about $664,000. Tidal Investments LLC lifted its position in shares of COMPASS Pathways by 43.6% in the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after buying an additional 5,795 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of COMPASS Pathways during the 1st quarter worth about $201,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CMPS. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Royal Bank of Canada decreased their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Maxim Group lowered their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, HC Wainwright cut their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $30.67.

COMPASS Pathways Trading Up 0.8 %

Shares of CMPS stock opened at $4.60 on Friday. The firm has a market capitalization of $314.39 million, a P/E ratio of -2.09 and a beta of 2.29. COMPASS Pathways plc has a 1 year low of $4.05 and a 1 year high of $12.75. The firm’s fifty day simple moving average is $5.63 and its 200 day simple moving average is $6.57. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the business earned ($0.67) earnings per share. As a group, sell-side analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. This trade represents a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.25% of the stock is owned by company insiders.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.